Abstract
Description
The Bladder Cancer Partnering 2007-2013 report provides understanding and
access to the bladder cancer partnering deals and agreements entered into by
the worlds leading healthcare companies.
- Trends in bladder cancer partnering deals
- Top bladder cancer deals by value
- Deals listed by company A-Z, industry sector, stage of development,
technology type
The Bladder Cancer Partnering 2007-2013 provides understanding and access to
the bladder cancer partnering deals and agreements entered into by the worlds
leading healthcare companies.
The report provides an analysis of bladder cancer partnering deals. The
majority of deals are discovery or development stage whereby the licensee
obtains a right or an option right to license the licensors bladder cancer
technology. These deals tend to be multicomponent, starting with collaborative
R&D, and commercialization of outcomes.
Understanding the flexibility of a prospective partner's negotiated deals
terms provides critical insight into the negotiation process in terms of what
you can expect to achieve during the negotiation of terms. Whilst many smaller
companies will be seeking details of the payments clauses, the devil is in the
detail in terms of how payments are triggered - contract documents provide
this insight where press releases do not.
This data driven report contains over 25 links to online copies of actual
bladder cancer deals and contract documents as submitted to the Securities
Exchange Commission by companies and their partners, where available. Contract
documents provide the answers to numerous questions about a prospective
partner's flexibility on a wide range of important issues, many of which will
have a significant impact on each party's ability to derive value from the
deal.
The initial chapters of this report provide an orientation of bladder cancer
partnering trends.
Chapter 1 provides an introduction to the report, whilst chapter 2 provides an
overview of the trends in bladder cancer partnering since 2007, including a
summary of deals by industry sector, stage of development, deal type, and
technology type. Numerous tables provide outline financial trends.
Chapter 3 provides an overview of the leading bladder cancer deals since 2007.
Deals are listed by headline value, signed by bigpharma, most active
bigpharma. Where the deal has an agreement contract published at the SEC a
link provides online access to the contract.
Chapter 4 provides a comprehensive directory of bladder cancer partnering
deals signed and announced since 2007. The chapter is organized by company
A-Z, stage of development at signing, deal type (collaborative R&D,
co-promotion, licensing etc), and technology type. Each deal title links via
Weblink to an online version of the deal record, and where available the
contract document, providing easy access to each contract document on demand.
In conclusion, this report provides everything a prospective dealmaker needs
to know about partnering in the research, development and commercialization of
bladder cancer technologies and products.
Report scope
Bladder Cancer Partnering 2007-2013 is intended to provide the reader with an
in-depth understanding and access to bladder cancer trends and structure of
deals entered into by leading companies worldwide.
This data driven report includes:
- Trends in bladder cancer dealmaking in the biopharma industry since 2007
- Access to summary headline, upfront, milestone and royalty data
- Access to over 25 bladder cancer contract documents
- The leading bladder cancer deals by value since 2007
In Bladder Cancer Partnering 2007-2013, the available deals are listed by:
- Headline value
- Upfront payment value
- Royalty rate value
- Company A-Z
- Industry sector
- Stage of development at signing
- Deal component type
- Technology type
Each deal title links via Weblink to an online version of the deal record and
where available, the contract document, providing easy access to each contract
document on demand.
Benefits
Bladder Cancer Partnering 2007-2013 provides the reader with the following key benefits:
- In-depth understanding of bladder cancer deal trends since 2007
- Access to summary headline, upfront, milestone and royalty data
- Comprehensive access to over 25 actual bladder cancer deals entered into
by the world's biopharma companies since 2007
- Insight into key deal terms included in contracts, where disclosed
- Understand the key deal terms companies have agreed in deals
- Undertake due diligence to assess suitability of your proposed deal terms
for partner companies
Table of Contents
Executive Summary
Chapter 1 - Introduction
Chapter 2 - Trends in bladder cancer partnering
- 2.1. Introduction
- 2.2. Bladder cancer partnering over the years
- 2.3. Bigpharma bladder cancer dealmaking activity
- 2.4. Bladder cancer partnering by deal type
- 2.5. Bladder cancer partnering industry sector
- 2.6. Bladder cancer partnering by stage of development
- 2.7. Bladder cancer partnering by technology type
- 2.8. Disclosed financial deal terms for bladder cancer partnering
- 2.8.1 Bladder cancer headline values
- 2.8.2 Bladder cancer upfront payments
- 2.8.3 Bladder cancer milestone payments
- 2.8.4 Bladder cancer royalty rates
Chapter 3 - Leading bladder cancer deals
- 3.1. Introduction
- 3.2. Top bladder cancer deals by value
- 3.3. Top bladder cancer deals involving bigpharma
Chapter 4 - Dealmaking directory
- 4.1. Introduction
- 4.2. Company A-Z
- 4.3. By deal type
- Asset purchase
- Bigpharma outlicensing
- Co-development
- Collaborative R&D
- Co-market
- Contract service
- Co-promotion
- CRADA
- Cross-licensing
- Development
- Distribution
- Equity purchase
- Evaluation
- Grant
- Joint venture
- Licensing
- Manufacturing
- Marketing
- Option
- Promotion
- Research
- Settlement
- Spin out
- Sub-license
- Supply
- Termination
- 4.4. By industry sector
- Academic
- Bigpharma
- Biotech
- Drug delivery
- Medical device
- Diagnostic
- Generic pharma
- Government
- Non-profit
- Pharmaceutical
- Research tools
- Services
- Specialty pharma
- 4.5. By stage of development
- Discovery
- Pre-clinical
- Phase I
- Phase II
- Phase III
- Registration
- Marketed
- 4.6. By technology type
- Analysis
- Animal models
- Assays
- Bioinformatics
- Biological compounds
- Biomarkers
- Biomaterials
- Cell culture
- Cell therapy
- Clinical testing
- Diagnostic - companion
- Devices
- Diagnostics
- Discovery tools
- DNA probes
- Drug delivery
- Enabling technology
- Epigenetics
- Equipment
- Facilities
- Gene therapy
- Genomics
- Imaging
- Industrial chemicals
- In vitro models
- Monoclonal antibodies
- Nanotechnology
- Oligonucleotide
- Peptides
- Personalised medicine
- Processes
- Proteomics
- Radio/Chemo-therapy
- Recombinant DNA
- Research services
- Research supplies
- RNA therapeutics
- Screening
- Small molecules
- Stem cells
- Vaccines
Chapter 5 - Partnering resource center
- 5.1. Online partnering
- 5.2. Partnering events
- 5.3. Further reading on dealmaking
Appendices
- Appendix 1 - Deal type definitions
About Wildwood Ventures
- Current Partnering
- Current Agreements
- Recent titles from CurrentPartnering
- Order Form - Reports
Table of figures
- Figure 1: Bladder cancer partnering since 2007
- Figure 2: Bigpharma - top 50 - bladder cancer deals 2007 to 2013
- Figure 3: Bigpharma bladder cancer deal frequency - 2007 to 2013
- Figure 4: Bladder cancer partnering by deal type since 2007
- Figure 5: Bladder cancer partnering by industry sector since 2007
- Figure 6: Bladder cancer partnering by stage of development since 2007
- Figure 7: Bladder cancer partnering by technology type since 2007
- Figure 8: Bladder cancer deals with a headline value
- Figure 9: Bladder cancer deals with upfront payment values
- Figure 10: Bladder cancer deals with milestone payments
- Figure 11: Bladder cancer deals with royalty rates, %
- Figure 12: Top bladder cancer deals by value since 2007
- Figure 13: Top bladder cancer deals signed by bigpharma value since 2007
- Figure 14: Online partnering resources
- Figure 15: Forthcoming partnering events
- Figure 16: Deal type definitions
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
